Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: BP p.l.c.: Director/PDMR Shareholding: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23826/BP_logo.svg.png
DGAP-News: BP p.l.c.: Director/PDMR Shareholding
DGAP-News: BP p.l.c.: Director/PDMR Shareholding
Nine in 10 Insurance Leaders in Europe Say Customer Experience is the Top Driver of Digital Transformation: https://mms.businesswire.com/media/20210201005142/en/1016900/5/ISG_%28R%29_Logo.jpg
Nine in 10 Insurance Leaders in Europe Say Customer Experience is the Top Driver of Digital Transformation


Demand for improved customer experience is the top driver of digital transformation in Europe’s insurance industry, but with growing digitalization, insurers report increasing security

Northern Trust Launches New Climate Focus Reporting: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24662/Northern_trust_logo16.png
Northern Trust Launches New Climate Focus Reporting


Northern Trust (Nasdaq: NTRS) has further enhanced its suite of environmental, social and governance (ESG) investment analytics to deliver new climate risk reporting for global institutional

DGAP-News: Vonovia SE: Vonovia SE expands Management Board: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23633/Vonovia_Logo.svg.png
DGAP-News: Vonovia SE: Vonovia SE expands Management Board
DGAP-News: Vonovia SE: Vonovia SE expands Management Board
Eurofins Technologies launches new Lateral Flow Reader RapidScan ST5-W as a single platform validated for multiple food and environmental rapid tests: https://mms.businesswire.com/media/20200421005718/en/318625/5/EUROFINS_jpg.jpg
Eurofins Technologies launches new Lateral Flow Reader RapidScan ST5-W as a single platform validated for multiple food and environmental rapid tests


Eurofins Technologies (Paris:ERF), a supplier of test kits and systems for laboratory analyses, announces the launch of its new RapidScan ST5-W lateral flow reader, specifically designed for field

Vifor Pharma comments on media speculation: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma comments on media speculation


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this

Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID: https://mms.businesswire.com/media/20210924005283/en/519367/5/GeNeuro_-_logo.jpg
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID


Regulatory News:



GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final

Gensource Potash Announces Filing of Base Shelf Prospectus: https://mms.businesswire.com/media/20191203005382/en/760080/5/4086210_4074832_4068077_3946158_logo.jpg
Gensource Potash Announces Filing of Base Shelf Prospectus


Gensource Potash Corporation (“Gensource” or the “Company”) (TSXV: GSP, AIM: GSP) today announced that it has filed and obtained a final receipt (the “Receipt”) for a final short form base shelf

Elliptic Labs Signs Software License Agreement with New Smartphone Customer for Seven Smartphone Models: https://mms.businesswire.com/media/20210527005056/en/881206/5/ellipticlabs-logo-blue.jpg
Elliptic Labs Signs Software License Agreement with New Smartphone Customer for Seven Smartphone Models


Elliptic Labs (EuroNext Growth: ELABS.OL), a global AI software company and the world leader in AI Virtual Smart SensorsTM, has signed a license agreement with a new Asia-based smartphone

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy


Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene

Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc

DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting


Regulatory News:



MaaT Pharma (EURONEXT: MAAT - the “Company“), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving

DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
RRD Board Unanimously Determines that Chatham’s Unsolicited Proposal to Acquire RRD for $10.85 Per Share in Cash Constitutes a “Superior Proposal”
RRD Board Unanimously Determines that Chatham’s Unsolicited Proposal to Acquire RRD for $10.85 Per Share in Cash Constitutes a “Superior Proposal”


R.R. Donnelley & Sons Company (NYSE: RRD) (“RRD” or the “Company”) announced today that its Board of Directors (the “Board”) unanimously determined that an unsolicited proposal from Chatham Asset

Essex Property Trust Declares Quarterly Distributions: https://mms.businesswire.com/media/20191108005660/en/625771/5/Essex_Logo_Black_%28002%29.jpg
Essex Property Trust Declares Quarterly Distributions


Essex Property Trust, Inc. (NYSE:ESS) announced today that its Board of Directors has declared a regular quarterly cash dividend of $2.09 per common share, payable January 14, 2022 to shareholders

SunMirror AG: Expanding the Team to Support the Execution of the Growth Strategy into Critical Raw Materials
SunMirror AG: Expanding the Team to Support the Execution of the Growth Strategy into Critical Raw Materials


SunMirror AG ("SunMirror", "the Company"; Vienna Stock Exchange: ROR1; Frankfurt Stock Exchange: ROR; ISIN CH0396131929) is pleased to announce experienced senior executives to join the SunMirror's

Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented an update from its Phase II SUMMIT trial at the ongoing 2021 San Antonio Breast Cancer Symposium (SABCS) Annual

DGAP-Adhoc: United Internet AG: Ralph Dommermuth assesses offers for block acquisitions of shares in United Internet AG: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24075/330px-UnitedInternet_logo.svg.png
DGAP-Adhoc: United Internet AG: Ralph Dommermuth assesses offers for block acquisitions of shares in United Internet AG
DGAP-Adhoc: United Internet AG: Ralph Dommermuth assesses offers for block acquisitions of shares in United Internet AG
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease


Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult

Pfizer Declares First-Quarter 2022 Dividendhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Declares First-Quarter 2022 Dividend


Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.40 for the first-quarter 2022 dividend

DGAP-News: BP p.l.c.: Transaction in Own Shares: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23826/BP_logo.svg.png
DGAP-News: BP p.l.c.: Transaction in Own Shares
DGAP-News: BP p.l.c.: Transaction in Own Shares
Energy Secretary Jennifer M. Granholm Highlights Clean Energy Investments on Tour of Exelon Nuclear Plant: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24420/375px-Exelon_Corp_logo.png
Energy Secretary Jennifer M. Granholm Highlights Clean Energy Investments on Tour of Exelon Nuclear Plant


Exelon Corp. (Nasdaq: EXC) hosted U.S. Secretary of Energy Jennifer M. Granholm on a tour of Exelon’s Braidwood Generating Station in Will County to highlight the economic and environmental

Okta Joins the OpenID Foundation Board to Further Advance Open Identity Standards
Okta Joins the OpenID Foundation Board to Further Advance Open Identity Standards


Okta, Inc. (NASDAQ:OKTA), the leading independent provider of identity, today announced it has joined the OpenID Foundation as a sustaining member. The new board position for Okta follows